Today, 36 million people in the European Union (EU) and 30 million in the US with a rare disease face the harsh reality of a ...

Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid ...

The first company to take up residence in Bayer Co.Lab Berlin – initially located on the group's pharma headquarters site in ...

A strategy for women's health in England was published in 2022 under the previous Conservative government, led at the time by ...

Adcendo has tapped into the strong investor appetite for companies developing antibody-drug conjugates for cancer with an ...

In a post on X.com, Neuralink said it had been granted regulatory approval for "a new feasibility trial to extend BCI control ...

The FDA is scrutinising reports of haematological cancers in patients treated with bluebird bio's gene therapy for the rare ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, ...

In a statement, Applied Tx said it is reviewing the complete response letter (CRL) from the FDA and "plans to immediately ...

Healthcare professionals (HCPs) expect digital experiences to be as seamless and personalised as the apps and services they ...

“It’s a really exciting time, not just for NWEH, but also for the future of clinical trials in the UK. If successful, this ...

The European Commission has cleared use of CDK4/6 inhibitor Kisqali (ribociclib) to reduce the risk of recurrence in patients ...